Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 11/02/26
PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow's Eye Care PortfolioBusiness Wire • 11/02/26
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026GlobeNewsWire • 10/26/26
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAOGlobeNewsWire • 09/30/26
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal InjectionsGlobeNewsWire • 08/20/26
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye DiseaseGlobeNewsWire • 08/06/26
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026GlobeNewsWire • 07/27/26